Celecoxib
Published on: 2024-01-04 | No of Pages : 138 | Industry : Pharma & Healthcare
Publisher : HNY Research | Format : PDF&Excel
Celecoxib
The global Celecoxib market was valued at 1158.64 Million USD in 2021 and will grow with a CAGR of 8.91% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Celecoxib capsules (patent brand nameCELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs. Data show that more than 400 million people worldwide are currently affected by joint diseases. The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75. The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing. At present, the burden of chronic diseases will increase by 40% due to the aging of the population. As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth. Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice. At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years. At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly. It accounted for 63.39% of the global market in 2019. As of 2019, China relies entirely on Pfizer for celecoxib imports. Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
By Market Verdors
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
By Types
50mg
100mg
200mg
400mg
By Applications
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Celecoxib capsules (patent brand nameCELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs. Data show that more than 400 million people worldwide are currently affected by joint diseases. The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75. The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing. At present, the burden of chronic diseases will increase by 40% due to the aging of the population. As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth. Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice. At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years. At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly. It accounted for 63.39% of the global market in 2019. As of 2019, China relies entirely on Pfizer for celecoxib imports. Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
By Market Verdors
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
By Types
50mg
100mg
200mg
400mg
By Applications
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices